Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Liver cancer

Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma

Nature Reviews Clinical Oncology volume 22, pages 625–626 (2025)Cite this article

Subjects

Immune-checkpoint inhibitors have revolutionized the management of hepatocellular carcinoma. Currently, anti-PD-(L)-1 antibodies combined with either bevacizumab or anti-CTLA4 antibodies are the standard of care for advanced-stage tumours. Now, two phase III studies (CheckMate 9DW and APOLLO) have reported positive survival results in the first-line setting, although with distinct implications for clinical practice.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).

    Article  PubMed  Google Scholar 

  2. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

    Article  CAS  PubMed  Google Scholar 

  3. Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).

    Article  CAS  PubMed  Google Scholar 

  4. Abou-Alfa, G. K. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1, EVIDoa2100070 (2022).

    Article  PubMed  Google Scholar 

  5. Cappuyns, S. et al. Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma. J. Hepatol. 82, 1036–1049 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151–172 (2022).

    Article  CAS  PubMed  Google Scholar 

  7. Yau, T. et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet 405, 1851–1864 (2025).

    Article  CAS  PubMed  Google Scholar 

  8. Zhou, J. et al. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial. Lancet Oncol. 26, 719–731 (2025).

    Article  CAS  PubMed  Google Scholar 

  9. Llovet, J. M. et al. Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival. J. Hepatol. 70, 1262–1277 (2019).

    Article  PubMed  Google Scholar 

  10. Llovet, J. M. et al. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology 73, 158–191 (2021).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mount Sinai Liver Cancer Program, Divisions of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Josep M. Llovet

  2. Liver Cancer Translational Research Group, Liver Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

    Josep M. Llovet

  3. Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain

    Josep M. Llovet

Authors
  1. Josep M. Llovet
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Josep M. Llovet.

Ethics declarations

Competing interests

J.M.L. receives consulting fees from AbbVie, AstraZeneca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Eisai, Genentech, Glycotest, Merck, Roche and Sanofi Aventis, and research support from Eisai.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Llovet, J.M. Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma. Nat Rev Clin Oncol 22, 625–626 (2025). https://doi.org/10.1038/s41571-025-01055-5

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-025-01055-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing